Chobani Gets FDA Permission To Break Yogurt Rules While Testing Recipes
Published Date: 6/18/2025
Notice
Summary
The FDA is letting Chobani keep testing new yogurt recipes that don’t follow the usual rules, using ultrafiltered milk to make lower-fat options. This temporary permit helps Chobani see if customers like these yogurts and gather info to possibly change yogurt rules. Other companies can join the test, and the permit lasts until the new yogurt rules are set or the petition is denied.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Other firms may join test with labeling and notice rules
FDA invites other firms to join the extended market test but requires them to notify FDA of intent, list products, area of distribution, amount to be distributed, and submit draft labels. Labels for test products must include nutrition labeling per 21 CFR 101.9 and declare all ingredients as required by 21 CFR part 101.
Permit extended to market-test ultrafiltered yogurt
Chobani is allowed to continue market testing yogurt made using ultrafiltered nonfat milk, with a permit authorizing up to 150,000,000 pounds (68,038,855.5 kg) of test product annually. The permit will expire either on the effective date of any final rule changing the yogurt standard of identity or 30 days after denial of the petition.
Clarified ingredient allowance: UF milk, water, sweeteners
FDA amended Chobani's permit to clarify it allows manufacturing yogurt and lower-fat yogurt products using ultrafiltered (UF) nonfat milk as a basic dairy ingredient and using water and nonnutritive sweeteners. The amendment also applies when those yogurt products are used, in whole or in part, as ingredients in nonstandardized foods.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11205, Certain Frozen Fish Fillets From the Socialist Republic of Vietnam: Final Results and Partial Rescission of Administrative Review; 2022-2023
The U.S. Department of Commerce reviewed frozen fish fillets from Vietnam and found that Bien Dong Seafood didn’t sell their fish at unfairly low prices from August 2022 to July 2023. Six other Vietnamese seafood companies earned special status, and the review for the Vietnam-wide group was canceled. These decisions, effective June 18, 2025, could affect import duties and trade fairness.
Next: 2025-11209, Cheese Products Deviating From Standard of Identity; Temporary Permit for Market Testing
The FDA is letting Bongards' Creameries keep testing a special cheese that uses extra virgin olive oil to stop slices from sticking, even though it breaks the usual cheese rules. They've updated the permit to focus on one type of cheese and extended the testing period while they gather feedback and decide if the cheese rules should change. Other cheese makers can join in, and the permit lasts until a final decision is made or 30 days after a denial.